Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Part of paid clinical trials in Bay City, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT07130903
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Colorectal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fruquintinib — DRUG
    Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
  • TheraBionic P1 — DEVICE
    TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device

Study Details

The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable

Key Dates

Start date
Sep 10, 2025
Status verified
Nov 2025
Primary completion
Apr 17, 2028
Completion
Apr 17, 2030

Study Design

Enrollment
102 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Amplitude-modulated radiofrequency electromagnetic fields device plus Fruquintinib
    TheraBionic P1 amplitude-modulated radiofrequency electromagnetic fields device 3 times daily (continuous) plus Fruquintinib daily (3 weeks on and 1 week off)

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: From start of treatment to 5 years after treatment discontinuation or death, whichever comes first ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Karmanos Cancer Institute at McLaren Bay RegionBay CityMichigan48706
Mohammed N Al Hallak, M.D.
Karmanos Cancer Institute at McLaren ClarkstonClarkstonMichigan48346
Mohammed N Al Hallak, MD
Karmanos Cancer InstituteDetroitMichigan48201
Mohammed N Al Hallak, MD
1-800-527-6266
Karmanos Cancer Institute at McLaren FlintFlintMichigan48532
Mohammed N Al Hallak, MD
Karmanos Cancer Institute at McLaren Greater LansingLansingMichigan48910
Mohammed N Al Hallak, MD
Karmanos Cancer Institute at McLaren Lapeer RegionLapeerMichigan48446
Mohammed N Al Hallak, MD
Karmanos Cancer Institute at McLaren MacombMacombMichigan48043
Mohammed N Al Hallak, MD
Karmanos Cancer Institute at McLaren Northern Michigan, PetoskeyPetoskeyMichigan49770
Mohammed N Al Hallak, MD
Karmanos Cancer Institute at McLaren Port HuronPort HuronMichigan48060
Mohammed N Al Hallak, MD

Find similar trials in Bay City, MI

By research site
Karmanos Cancer Institute at McLaren Bay Region· Bay City, MIKarmanos Cancer Institute at McLaren Clarkston· Clarkston, MIKarmanos Cancer Institute· Detroit, MIKarmanos Cancer Institute at McLaren Flint· Flint, MIKarmanos Cancer Institute at McLaren Greater Lansing· Lansing, MIKarmanos Cancer Institute at McLaren Lapeer Region· Lapeer, MI

Related Studies